TG Therapeutics, Inc. (TGTX) Insider Trading

Last 12 months

Insiders sold $438k and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. The last open-market buy by an executive or director was in Aug 2023.

Net open-market

−$438k

0 buys · 2 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 2

executives and directors

Last open-market buy

Aug 2023

Aug 11, 2023

Get an email when TGTX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 10	Laurence N Charney Director	SoldNo plan	5,000	$54.96	$275k	2.9%	Form 4
Nov 24, 2025	Yann Echelard Director	SoldNo plan	5,000	$32.57	$163k	2.2%	Form 4
Sep 11, 2025	Sagar Lonial Director	SoldNo plan	20,852	$32.24	$672k	18%	Form 4
Jun 13, 2025	Yann Echelard Director	SoldNo plan	10,000	$36.94	$369k	4.2%	Form 4
Jan 3, 2025 – Jan 6, 2025	Sean A Power CFO	SoldNo plan 2 parts	21,358	$29.46 average	$629k	3.1%	Form 4
Nov 11, 2024	Sagar Lonial Director	SoldNo plan	5,000	$30.44	$152k	4.8%	Form 4
Nov 11, 2024	Laurence N Charney Director	SoldNo plan	25,000	$30.20	$755k	11%	Form 4
Nov 5, 2024	Yann Echelard Director	SoldNo plan	20,000	$24.48	$490k	8.2%	Form 4

Sep 10No plan
Laurence N Charney
Director · sold 5,000 at $54.96
$275k
2.9% of stake
Nov 24, 2025No plan
Yann Echelard
Director · sold 5,000 at $32.57
$163k
2.2% of stake
Sep 11, 2025No plan
Sagar Lonial
Director · sold 20,852 at $32.24
$672k
18% of stake
Jun 13, 2025No plan
Yann Echelard
Director · sold 10,000 at $36.94
$369k
4.2% of stake
Jan 3, 2025 – Jan 6, 2025No plan
Sean A Power
CFO · sold 21,358 at avg $29.46
$629k
3.1% of stake
Nov 11, 2024No plan
Sagar Lonial
Director · sold 5,000 at $30.44
$152k
4.8% of stake
Nov 11, 2024No plan
Laurence N Charney
Director · sold 25,000 at $30.20
$755k
11% of stake
Nov 5, 2024No plan
Yann Echelard
Director · sold 20,000 at $24.48
$490k
8.2% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch TGTX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Pharmaceutical Preparations

COLLCollegium Pharmaceutical Inc.

AXSMAxsome Therapeutics, Inc.

EBSEmergent BioSolutions Inc.

SUPNSupernus Pharmaceuticals Inc.

CORTCorcept Therapeutics Incorporated

KNSAKiniksa Pharmaceuticals International, plc

PCRXPacira BioSciences Inc.

AMPHAmphastar Pharmaceuticals Inc.

Spot a number that looks wrong? Check it in TGTX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing TGTX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.